SG10201801321XA - Formulations of quinones for the treatment of ophthalmic diseases - Google Patents
Formulations of quinones for the treatment of ophthalmic diseasesInfo
- Publication number
- SG10201801321XA SG10201801321XA SG10201801321XA SG10201801321XA SG10201801321XA SG 10201801321X A SG10201801321X A SG 10201801321XA SG 10201801321X A SG10201801321X A SG 10201801321XA SG 10201801321X A SG10201801321X A SG 10201801321XA SG 10201801321X A SG10201801321X A SG 10201801321XA
- Authority
- SG
- Singapore
- Prior art keywords
- quinones
- formulations
- treatment
- ophthalmic diseases
- ophthalmic
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
- A61K31/122—Ketones having the oxygen directly attached to a ring, e.g. quinones, vitamin K1, anthralin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Psychiatry (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US32854610P | 2010-04-27 | 2010-04-27 | |
| US39369310P | 2010-10-15 | 2010-10-15 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG10201801321XA true SG10201801321XA (en) | 2018-04-27 |
Family
ID=44861894
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG10201801321XA SG10201801321XA (en) | 2010-04-27 | 2011-04-26 | Formulations of quinones for the treatment of ophthalmic diseases |
| SG2012079323A SG185046A1 (en) | 2010-04-27 | 2011-04-26 | Formulations of quinones for the treatment of ophthalmic diseases |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG2012079323A SG185046A1 (en) | 2010-04-27 | 2011-04-26 | Formulations of quinones for the treatment of ophthalmic diseases |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20130109759A1 (fr) |
| EP (1) | EP2563352A4 (fr) |
| JP (2) | JP5902673B2 (fr) |
| CN (2) | CN105147651A (fr) |
| AU (1) | AU2011245384C1 (fr) |
| BR (1) | BR112012027543A8 (fr) |
| CA (1) | CA2797581A1 (fr) |
| EA (1) | EA201201465A1 (fr) |
| MX (1) | MX337594B (fr) |
| MY (1) | MY183449A (fr) |
| SG (2) | SG10201801321XA (fr) |
| WO (1) | WO2011137126A1 (fr) |
| ZA (1) | ZA201208535B (fr) |
Families Citing this family (29)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2583087C (fr) | 2003-09-19 | 2012-07-10 | Galileo Pharmaceuticals, Inc. | Derives de chromane |
| DK2564843T3 (en) | 2005-06-01 | 2019-03-11 | Bioelectron Tech Corp | Redox-active therapeutics for the treatment of mitochondrial diseases and other conditions as well as modulation of energy biomarkers |
| JP5374162B2 (ja) | 2006-02-22 | 2013-12-25 | エジソン ファーマシューティカルズ， インコーポレイテッド | ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節 |
| PL3456707T3 (pl) | 2007-11-06 | 2020-09-21 | Ptc Therapeutics, Inc. | Pochodne 4-(p-chinonylo)-2-hydroksybutanamidu do leczenia chorób mitochondrialnych |
| US8952071B2 (en) * | 2008-01-08 | 2015-02-10 | Edison Pharmaceuticals, Inc. | (Het)aryl-p-quinone derivatives for treatment of mitochondrial diseases |
| WO2009111576A2 (fr) | 2008-03-05 | 2009-09-11 | Edison Pharmaceuticals, Inc. | Dérivés de p-quinone 2-substituée pour le traitement de maladies de stress oxydatif |
| EP2303824B1 (fr) * | 2008-06-25 | 2015-03-25 | Edison Pharmaceuticals, Inc. | Dérivés 2-hétérocyclylaminoalkyl-(p-quinone) pour traiter les maladies liées à un stress oxydatif |
| US8314153B2 (en) | 2008-09-10 | 2012-11-20 | Edison Pharmaceuticals, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
| WO2010045220A1 (fr) | 2008-10-14 | 2010-04-22 | Edison Pharmaceuticals, Inc. | Traitement d'affections liées au stress oxydatif, notamment de la néphropathie aux produits de contraste, des radiolésions et des perturbations de la fonction des globules rouges |
| EP3450431B1 (fr) | 2008-10-28 | 2023-09-13 | PTC Therapeutics, Inc. | Procédé de production d'alpha-tocotriénol et de ses dérivés |
| EA031126B1 (ru) | 2009-04-28 | 2018-11-30 | Биоэлектрон Текнолоджи Корпорейшн | Способ лечения доминантной атрофии зрительного нерва токотриенол-хинонами |
| MX337990B (es) * | 2009-08-26 | 2016-03-30 | Edison Pharmaceuticals Inc | Metodos para la prevencion y tratamiento de isquemia cerebral. |
| JP2013523816A (ja) * | 2010-04-06 | 2013-06-17 | エジソン ファーマシューティカルズ， インコーポレイテッド | 毛細血管拡張性運動失調症の治療 |
| JP5902673B2 (ja) * | 2010-04-27 | 2016-04-13 | エジソン ファーマシューティカルズ， インコーポレイテッド | 眼疾患の処置のためのキノンの製剤 |
| US9464016B2 (en) | 2011-06-14 | 2016-10-11 | Edison Pharmaceuticals, Inc. | Catechol derivatives for treatment of oxidative stress diseases |
| WO2013013078A1 (fr) | 2011-07-19 | 2013-01-24 | Edison Pharmeceuticals, Inc. | Procédés pour l'oxydation sélective d'alpha-tocotriénol en présence de tocotriénols qui ne sont pas l'alpha-tocotriénol |
| WO2014039917A1 (fr) * | 2012-09-07 | 2014-03-13 | Edison Pharmaceuticals, Inc. | Dérivés de benzoquinone de traitement de troubles liés au stress oxydatif |
| WO2014145116A2 (fr) | 2013-03-15 | 2014-09-18 | Edison Pharmaceuticals, Inc. | Dérivés de quinone à groupe alkyle-hétéroaryle substitué de traitement de troubles de stress oxydatif |
| US9296712B2 (en) | 2013-03-15 | 2016-03-29 | Edison Pharmaceuticals, Inc. | Resorufin derivatives for treatment of oxidative stress disorders |
| US9670170B2 (en) | 2013-03-15 | 2017-06-06 | Bioelectron Technology Corporation | Resorufin derivatives for treatment of oxidative stress disorders |
| US9868711B2 (en) | 2013-03-15 | 2018-01-16 | Bioelectron Technology Corporation | Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders |
| PL3233786T3 (pl) | 2014-12-16 | 2022-06-13 | Ptc Therapeutics, Inc. | Polimorficzne i amorficzne postacie (r)-2-hydroksy-2-metylo-4-(2,4,5-trimetylo-3,6-dioksocykloheksa-1,4-dienylo)butanoamidu |
| JP7117241B2 (ja) | 2015-12-16 | 2022-08-12 | ピーティーシー セラピューティクス， インコーポレイテッド | 混合されたトコール組成物からアルファ－トコトリエノールを富化するための改良された方法 |
| CN108712903A (zh) | 2015-12-17 | 2018-10-26 | 生物电子技术有限公司 | 用于治疗氧化应急障碍的氟烷基、氟代烷氧基、苯氧基、杂芳氧基、烷氧基和胺1,4-苯醌衍生物 |
| JP2018083799A (ja) | 2016-11-15 | 2018-05-31 | バイオエレクトロン テクノロジー コーポレイション | ２−置換アミノ−ナフト［１，２−ｄ］イミダゾール−５−オン化合物またはその製薬学上許容される塩 |
| US11260048B2 (en) | 2017-10-03 | 2022-03-01 | The Schepens Eye Research Institute, Inc. | Compounds and compositions for inhibiting retinal pigment epithelium degeneration and methods using the same |
| KR20210076956A (ko) | 2018-10-17 | 2021-06-24 | 피티씨 테라퓨틱스, 인크. | α-시누클레인병증, 타우병증 및 기타 장애를 억제 및 치료하기 위한 2,3,5-트리메틸-6-노닐사이클로헥사-2,5-디엔-1,4-디온 |
| US20220226443A1 (en) * | 2019-05-28 | 2022-07-21 | Elgan Pharma Ltd | Compositions and methods for treating retinopathy |
| EP4366700A1 (fr) | 2021-07-08 | 2024-05-15 | PTC Therapeutics, Inc. | Compositions pharmaceutiques comprenant de la 2,3,5-triméthyl-6-nonylcyclohexa -2,5-diène-1,4-dione |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DK2564843T3 (en) * | 2005-06-01 | 2019-03-11 | Bioelectron Tech Corp | Redox-active therapeutics for the treatment of mitochondrial diseases and other conditions as well as modulation of energy biomarkers |
| CA2602440A1 (fr) * | 2005-09-16 | 2007-04-05 | Allergan, Inc. | Compositions et methodes pour le transport intraoculaire d'agents therapeutiques |
| JP5374162B2 (ja) * | 2006-02-22 | 2013-12-25 | エジソン ファーマシューティカルズ， インコーポレイテッド | ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節 |
| US8314153B2 (en) * | 2008-09-10 | 2012-11-20 | Edison Pharmaceuticals, Inc. | Treatment of pervasive developmental disorders with redox-active therapeutics |
| MX337990B (es) * | 2009-08-26 | 2016-03-30 | Edison Pharmaceuticals Inc | Metodos para la prevencion y tratamiento de isquemia cerebral. |
| JP2013523816A (ja) * | 2010-04-06 | 2013-06-17 | エジソン ファーマシューティカルズ， インコーポレイテッド | 毛細血管拡張性運動失調症の治療 |
| JP5902673B2 (ja) * | 2010-04-27 | 2016-04-13 | エジソン ファーマシューティカルズ， インコーポレイテッド | 眼疾患の処置のためのキノンの製剤 |
-
2011
- 2011-04-26 JP JP2013508167A patent/JP5902673B2/ja not_active Expired - Fee Related
- 2011-04-26 MX MX2012012518A patent/MX337594B/es active IP Right Grant
- 2011-04-26 AU AU2011245384A patent/AU2011245384C1/en not_active Ceased
- 2011-04-26 WO PCT/US2011/033983 patent/WO2011137126A1/fr active Application Filing
- 2011-04-26 SG SG10201801321XA patent/SG10201801321XA/en unknown
- 2011-04-26 MY MYPI2012004738A patent/MY183449A/en unknown
- 2011-04-26 SG SG2012079323A patent/SG185046A1/en unknown
- 2011-04-26 BR BR112012027543A patent/BR112012027543A8/pt not_active IP Right Cessation
- 2011-04-26 CN CN201510490746.XA patent/CN105147651A/zh active Pending
- 2011-04-26 US US13/643,542 patent/US20130109759A1/en not_active Abandoned
- 2011-04-26 EP EP11775506.6A patent/EP2563352A4/fr not_active Withdrawn
- 2011-04-26 EA EA201201465A patent/EA201201465A1/ru unknown
- 2011-04-26 CA CA2797581A patent/CA2797581A1/fr not_active Abandoned
- 2011-04-26 CN CN2011800317444A patent/CN102985083A/zh active Pending
-
2012
- 2012-11-13 ZA ZA2012/08535A patent/ZA201208535B/en unknown
-
2016
- 2016-03-10 JP JP2016046881A patent/JP6266674B2/ja not_active Expired - Fee Related
-
2017
- 2017-01-17 US US15/407,831 patent/US20170354618A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| BR112012027543A2 (pt) | 2019-05-28 |
| EP2563352A1 (fr) | 2013-03-06 |
| AU2011245384A1 (en) | 2012-12-06 |
| EP2563352A4 (fr) | 2013-11-13 |
| US20130109759A1 (en) | 2013-05-02 |
| SG185046A1 (en) | 2012-12-28 |
| AU2011245384C1 (en) | 2016-09-01 |
| MY183449A (en) | 2021-02-18 |
| JP5902673B2 (ja) | 2016-04-13 |
| WO2011137126A1 (fr) | 2011-11-03 |
| CN105147651A (zh) | 2015-12-16 |
| EA201201465A1 (ru) | 2013-04-30 |
| JP2016106144A (ja) | 2016-06-16 |
| JP2013525443A (ja) | 2013-06-20 |
| US20170354618A1 (en) | 2017-12-14 |
| CN102985083A (zh) | 2013-03-20 |
| ZA201208535B (en) | 2016-06-29 |
| CA2797581A1 (fr) | 2011-11-03 |
| JP6266674B2 (ja) | 2018-01-24 |
| MX337594B (es) | 2016-03-11 |
| MX2012012518A (es) | 2012-12-17 |
| AU2011245384B2 (en) | 2016-02-18 |
| BR112012027543A8 (pt) | 2019-12-03 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA201208535B (en) | Formulations of quinones for the treatment of ophthalmic diseases | |
| ZA201403795B (en) | Formulations for the treatment of diabetes | |
| EP2621499A4 (fr) | Méthodes de traitement de maladies allergiques | |
| PT2925757T (pt) | Compostos e composições para o tratamento de doenças parasitárias | |
| HUE041553T2 (hu) | Lizoszomális tárolási betegségek (LSD) kezelése és génterápia | |
| EP2740482A4 (fr) | Agent prophylactique ou thérapeutique pour des maladies buccales | |
| ZA201301601B (en) | Treatment of diseases | |
| EP2613786A4 (fr) | Traitement de maladies | |
| GB2479213B (en) | Pharmaceutical formulations for the treatment of overactive bladder | |
| GB201021103D0 (en) | New compounds for the treatment of neurodegenerative diseases | |
| HK1186671A1 (en) | Formulations for the treatment of disorders of the upper respiratory tract | |
| EP2623494A4 (fr) | Agent pour le traitement de maladies oculaires | |
| IL275350B (en) | Treatment of neoplastic diseases | |
| GB0906159D0 (en) | Drug combination for the treatment of proteostatic diseases | |
| RS55173B1 (sr) | Uređaj i sistem za proizvodnju aerosola sa poboljšanim protokom vazduha | |
| ZA201305970B (en) | Arylosulfonami for the treatment of cns diseases | |
| EP2709632A4 (fr) | Compositions et procédés pour le traitement de maladies de la peau | |
| EP2723325A4 (fr) | Nouvelles formulations et méthodes de traitement de troubles ou de maladies dermatologiques | |
| GB201114289D0 (en) | Flurbiprofen and related compounds for the treatment of skin diseases | |
| HK1214771A1 (zh) | 用於治療皮膚病的製劑 | |
| EP2599776A4 (fr) | Agent thérapeutique pour des maladies neurologiques | |
| HK1196953A1 (zh) | 用於治療糖尿病的製劑 | |
| GB0901727D0 (en) | The treatment of ophthalmic diseases | |
| AU2011903764A0 (en) | Treatment of bone diseases | |
| HK1157189A1 (en) | Pharmaceutical composition for the treatment of tumor diseases |